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Abstract
Activation of the Ras-Raf–extracellular signal–regulated kinase (ERK) pathway causes not only proliferation and sup-
pression of apoptosis but also the antioncogenic response of senescence. How these contrasting effects are recon-
ciled to achieve cell transformation and cancer formation is poorly understood. In a system of two-step carcinogenesis
(dedifferentiated PC EIA, transformed PC EIA–polyoma–middle T [PC EIA + Py] and PC EIA–v-raf [PC EIA + raf] cells],
v-raf cooperated with EIA by virtue of a strong prosurvival effect, not elicited by Py–middle T, evident toward serum-
deprivation– and H2O2-induced apoptosis. Apoptosis was detected by DNA fragmentation and annexin V staining. The
prosurvival function of v-rafwas, in part, mitogen-activated protein kinase/ERK kinase (MEK)–dependent, as shown by
pharmacological MEK inhibition. TheMEK-dependent antiapoptotic effect of v-rafwas exerted despite a lower level of
P-ERK1/2 in EIA + raf cells with respect to EIA + Py/EIA cells, which was dependent on a high tyrosine phosphatase
activity, as shown by orthovanadate blockade. An ERK1/2 tyrosine phosphatase was likely involved. The high tyrosine
phosphatase activity was instrumental to the complete suppression of senescence, detected by β-galactosidase ac-
tivity, because tyrosine phosphatase blockade induced senescence in EIA+ raf but not in EIA+ Py cells. High tyrosine
phosphatase activity and evasion from senescence were confirmed in an anaplastic thyroid cancer cell line. There-
fore, besides EIA, EIA + raf cells suppress senescence through a new mechanism, namely, phosphatase-mediated
P-ERK1/2 inhibition, but, paradoxically, retain the oncogenic effects of the Raf-ERK pathway. We propose that the sur-
vival effect of Raf is not a function of absolute P-ERK1/2 levels at a given time but is rather dynamically dependent on
greater variations after an apoptotic stimulus.
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Introduction
TheRas-Raf–extracellular signal–regulated kinase (ERK) pathway is fre-
quently implicated in human cancers. Oncogenic mutations frequently
occur in Ras and B-Raf, and ERK is frequently hyperactivated in human
malignancies. Recently, mutations in C-Raf have been found in human
cancers, located between the regulatory and kinase domains [1,2]. Raf
kinase function has been analyzed well before the discovery of themuta-
tions occurring in cancers because activated version of A-, B-, and C-Raf
(including the retroviral version v-raf ) were transforming for a variety of
cell lines [3].
The mechanisms involved in Raf kinase transformation are stimula-
tion of cell cycle progression and cell survival. Raf stimulates cell cycle
progression mainly through transcriptional up-regulation of cyclin D1
and down-regulation of p27kip1 [4]. Several mechanisms have been
implicated in the survival activity of Raf. Described mechanisms re-
quire the kinase activity of Raf and mitogen-activated protein kinase/
ERK kinase (MEK) [5,6], or the kinase activity of Raf, but in a MEK-
independent manner. Thus, Raf activates, albeit indirectly, nuclear
factor κB (NF-κB) [7], it binds Bcl2 and BAG1 and is targeted to mito-
chondria where it exerts an antiapoptotic effect [8,9]. Finally, MEK-
independent and Raf kinase-independent mechanisms have been
reported. C-Raf binds to apoptosis signal regulating kinase (ASK1)
and mammalian sterile–twenty-like 2 (MST2) and suppresses their
proapoptotic activities in a kinase-independent manner [10,11]. Where
tested, the MEK-independent/kinase-independent mechanisms are
mediated by amino acids 151 to 303 of the regulatory N-terminus of
C-Raf [11]. A MEK- and kinase-independent mechanism of the pro-
survival function of Raf is also supported by in vivo data knocking in a
kinase-dead mutant of C-Raf [12]. However, some controversies exist
because the mutations used failed to completely inactivate Raf kinase
activity [13–15]. Although true kinase-dead mutants of C-Raf were as
efficient as wild-type Raf in interacting with MST2 and preventing
apoptosis, this has been demonstrated only in tissue culture models
[11]. In contrast, B-Raf V600E, that, bona fide, does not possess the
MEK-independent and kinase-independent functions of C-Raf (the
N-terminal domain of B-Raf is poorly homologous to that of C-Raf,
and in fact, B-Raf does not bind MST2 [11]) suppresses apoptosis
through an ERK-dependent BAD/BIM inactivation [16]. Therefore,
the mechanism(s) of Raf antiapoptotic activity are still debated.
However, oncogenic activation of several components of the Ras-
ERK pathway (Ras, C-Raf, B-Raf, MEK) induces cellular senescence
(oncogene-induced senescence,OIS) [17–19]. Thismechanism is opera-
tional in vivo, as demonstrated for murine lung adenomas, T-cell lym-
phomas, and benign melanocytic nevi [20–22].
Therefore, cancer cells exploit Raf activation for cell cycle progression
and protection toward apoptosis, but this activation (and in general,
an activation of the Ras-ERK pathway) may lead to OIS. Therefore,
senescence must be bypassed to achieve a fully neoplastic phenotype.
How this evasion is mediated is not completely understood. For exam-
ple, melanomas, in addition to Ras/Raf mutations, frequently harbor
inactivation of the INK4α/ARF tumor suppressor locus, which inacti-
vates the Rb (retinoblastoma) and p53 pathways [23]. However, it has
been observed, in human nevi and in BRAFE600-expressing melano-
cytes, a marked mosaic induction of p16INK4a [22]. This suggests that,
in melanomas, mechanisms other than p16INK4a inactivation contrib-
ute to protection against B-RafV600E–driven senescence. Thus, al-
though a mosaic inactivation of p16INK4a could reflect the presence of
senescent cells in the context of the tumor, it may be also indicative of
additional mechanism bypassing OIS. However, the nature of these
additional mechanisms and if they are operative in other cytotypes is
poorly understood.
In this study, we propose a new mechanism by which, at the same
time, EIA + Raf–transformed cells completely suppress OIS through a
phosphatase-mediated P-ERK1/2 inhibition, but, paradoxically, retain
the oncogenic effects of Raf-ERK pathway activation such as protection
from apoptosis, by a mechanism, at least in part, MEK-dependent.
Materials and Methods
Reagents and Antibodies
Sodium orthovanadate (OV), okadaic acid (OA), PD184352, and
U0126 were from Calbiochem (La Jolla, CA). Anti–P-ERK Tyr 205/
185 antibodies (sc-7383 able to detect P-Tyr 205/185 irrespective of
the state of Thr 203/183) and anti–P-ERK P-Thr 203/183 antibodies
(sc-101760 able to detect P-Thr 203/183 irrespective of the state
of Tyr 205/185), anti-ERK2, anti-p16INK4a, anti–C-Raf, anti-IκBα,
anti-Bcl2, anti–Bcl-XL, and anti-Bax antibodies were from Santa Cruz
Biotechnologies (Santa Cruz, CA). Secondary horseradish peroxidase–
conjugated antimouse and antirabbit antibodies were purchased from
Amersham (Piscataway, NJ).
Cell Culture
PC Cl3 cells were cultured in Coon modified Ham F-12 medium
supplemented with 5% calf serum (GIBCO, Grand Island, NY), a
six-hormone (6H)mixture as previously reported [24]. Dedifferentiated
and transformed PCCl3 cells (PC raf, PC Py, PCEIA, PCEIA + Py, and
PC EIA + raf; a gift fromDr A. Fusco) were grown in the samemedium
lacking the 6Hmixture. Anaplastic thyroid cancer FRO cells were a gift
from Dr M. Santoro. These cells harbor the BRAFV600E mutation and
are cultured in RPMI 1640 medium supplemented with 10% fetal
bovine serum.
To induce growth factor deprivation, cells were starved for different
times in a medium containing 0.2% BSA but lacking serum and hor-
mones. Alternatively, cells were treated withH2O2 at various concentra-
tions, with daily additions of freshly prepared H2O2.
Measurement of Apoptosis
Apoptosis was assessed by staining of cell membrane–exposed phos-
phatidylserine with fluorescein isothiocyanate–conjugated annexinVac-
cording to the manufacturer’s description (Pharmingen, San Diego,
CA). Samples were analyzed by flow cytometry using a FACSCalibur
(Beckman Instruments, Fullerton, CA), equippedwithModFit Software.
DNA fragmentation assay was performed as previously reported [25].
MTT Assay and Western Blot
Cells at 70%to80%confluencewere trypsinized (0.25%trypsinwith
1 mM EDTA), washed, resuspended in growth medium, and plated in
96-well plates with 0.1 ml of the 104 cell/ml cell suspension seeded in
each well. After an overnight incubation, cells were treated with specific
reagents for various times. The cell number was determined using a
modified MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tetrazolium
bromide) assay, as previously described [26]. The percentage of survival
was calculated as the absorbance ratio of treated to untreated cells. The
data presented are the mean ± SD from eight replicate wells per micro-
titer plate and replicated four times. For Western blot assays, cells were
treated with specific reagents (serum deprivation, H2O2, OV, OA) for
various times. At the end of the treatments, cells were washed with
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ice-cold phosphate-buffered saline (PBS) and harvested in Laemmli
buffer (with β-mercaptoethanol) containing a mixture of phosphatase
inhibitors (0.5 mM sodium vanadate, 2 mM sodium pyrophosphate,
5 mM β-glycerolphosphate, and 50 mM sodium fluoride) to prevent
postlysis dephosphorylation. Western blots were carried out as pre-
viously reported [24].
Senescence-Associated β-Galactosidase
Cells were washed twice with PBS (pH 7.2), fixed with 0.5% gluta-
raldehyde in PBS, and washed in PBS supplemented with 1 mM
MgCl2. Cells were stained at room temperature in X-Gal solution
(1 mg/ml X-Gal, 0.12 mM K3Fe[CN]6, 0.12 mM K4Fe[CN]6, and
1 mM MgCl2 in PBS at pH 6.0). Staining was performed for 10 to
12 hours. Cells were washed in PBS three times and photographed with
a Nikon AZ100 microscope equipped with a DS V1 camera (Nikon,
Tokyo, Japan). For each condition, two replicate plates, of three differ-
ent experiments, were examined. For each plate, staining was deter-
mined in four different microscope fields. The number of positively
stained cells was estimated and expressed as the percentage of the total
number of cells in the analyzed section. The microscopic fields were
examined by two observers independently. Interobserver disagreement
did not exceed 10% of the determined percent.
Figure 1. Transformed PC EIA + raf cells, but not transformed PC EIA + Py cells, are protected toward apoptosis triggered by growth factor
deprivation or H2O2. (A, B) Normal, dedifferentiated, and transformed PC Cl3 cells were kept in the presence of serum (and hormones for
normal PCCl3 cells) or deprivedof serum (andhormones for normal PCCl3 cells), but in the presenceof 0.2%BSA for 24, 48, and 96 hours (A)
and for 6, 24, and 48 hours (B). At the end of the periods in serum-starvedmedium, cells were harvested and subjected toMTT assay (A) and
DNA fragmentation assay (B) as outlined in Materials and Methods. In (A), the results shown are means ± SD from eight replicate wells per
microtiter plate of four different experiments. *P< .05, **P< .01, compared with untreated cells. (C, D) Dedifferentiated PC EIA and trans-
formed PC EIA + Py and PC EIA + raf cells were exposed to daily additions of 400 μMH2O2 for 24, 48, and 72 hours (C) or for 48 hours (D).
At the end of the treatments, cells were harvested and subjected to MTT assay (A) and annexin V staining (B) as outlined in Materials and
Methods. In (A), the results shown are means ± SD from eight replicate wells per microtiter plate of four different experiments. *P < .05,
**P < .01, compared with untreated cells.
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Results
Transformed PC EIA + raf Cells Are Protected toward
Apoptosis whereas Transformed PC EIA + Py Cells Are Not
In this study, we used a system of two-step carcinogenesis. Normal
cells are PC Cl3 cells, a differentiated rat thyroid epithelial cell line.
The transfection of the adenovirus EIA gene was able to dedifferentiate
PC Cl3 cells but was not able to transform them (PC EIA). A subse-
quent infection with PyMLV (carrying polyoma–middle T, PC EIA +
Py cells) or MSV3611 (carrying v-raf, PC EIA + raf cells) conferred to
PC EIA a high malignant phenotype. An infection of PC Cl3 with
MSV3611 (PC raf cells) did not transform them, whereas an infection
with PyMLV (PC Py cells) confers to PC Cl3 only a low tumorigenic
phenotype. This system has been widely used because it reproduces a
two-step carcinogenesis process in which the number and nature of
the gene involved are known, although the mechanism underlying the
cooperative effect of v-raf (and PyMT) with EIAwas not defined. How-
ever, it was clear that EIA + raf cells were more tumorigenic than EIA +
Py cells [27]. Because EIA confers to PC Cl3 a proliferation advantage
[27], we seek to test whether PyMT and v-raf transform PC EIA cells
through inhibition of apoptosis.
As shown in Figure 1A, growth factor deprivation did not modify cell
viability of PC Cl3, PC raf, and PC Py cells, whereas it dramatically in-
duced cell death in PC EIA and PC EIA + Py cells. However, PC EIA +
raf cells were completely protected by growth factor deprivation–
induced cell death. DNA fragmentation (Figure 1B) and propidium
iodide staining (not shown) experiments indicated the occurrence of
apoptotic cell death in EIA and EIA + Py cells. The marked apoptosis-
suppressive effect of v-raf was present also with a different stim-
ulus. Figure 1C shows that, after a daily addition of 400 μM H2O2,
there was a dramatic decrease in viability of EIA and EIA + Py cells,
but again, the EIA + raf cells were protected toward cell death. H2O2-
induced cell death was apoptotic, as shown by annexin V staining
(Figure 1D).
The v-raf Protective Effect Is, in Part, Mediated by Activation
of Its Substrate MEK
Next, we seek to verify if the potent inhibitory effect of v-raf on apop-
tosis was mediated by v-raf kinase–dependent mechanism. This was
reasonable because v-raf, lacking part of the N-terminal regulatory do-
main, may not be able to mediate the kinase- and MEK-independent
effects on apoptosis [11].
As shown in FigureW1, EIA + raf cells express high levels of p79 gag-
raf polyprotein and possibly low levels of p90 gag-raf polyprotein. The
endogenous p72 C-Raf is likely under the detection limit of the anti-
bodies (a similar differential expression, p79 > p90 > endogenous
p72, has been reported [28]). Next, we explored ERK1/2 phosphoryla-
tion after apoptotic stimuli (Figure 2, A and B). In normal growth con-
ditions, the analysis of the levels of P-ERK1/2 gave an unexpected result:
despite the presence of a constitutively activated raf (Figure W1), EIA +
raf cells displayed the lowest level of P-ERK1/2, approximately three
times lower than EIA + Py cells, which showed the highest (Figures 2,
3, and 5). Growth factor deprivation caused a decrease in P-ERK1/2 in
EIA and EIA + Py cells but not in EIA + raf cells (Figure 2A). AfterH2O2
addition, EIA and EIA + Py cells showed a slight increase in P-ERK1/2
levels (∼1.3-fold), whereas EIA + raf cells experienced a greater P-ERK1/
2 induction (∼2.5-fold; Figure 2B). However, even after serum depriva-
tion and H2O2, the absolute levels of P-ERK1/2 in EIA + raf cells were
not greater than those in EIA and EIA + Py cells.
Because one mechanism of the prosurvival function of Raf is MEK-
dependent [5,6], we seek to verify our intriguing findings (low absolute
levels of P-ERK1/2, but high variations of P-ERK1/2 after an apoptotic
stimulus in EIA + raf cells) with this possibility. Preliminarily, we deter-
mined the sensitivity of P-ERK1/2 levels to the specific MEK inhibitor
PD184352. As shown in Figure 3, the effect of PD184352 was more
evident in cells grown in serum (H2O2 addition) than in cells grown
in BSA. This is easily explained by (for example) different uptake rates
of the drug in the two conditions. A greater efficacy of PD184352 in
inhibiting the P-ERK levels in EIA + raf cells with respect to EIA + Py
cells is also evident. From these experiments, we took the lowest con-
centrations of PD184352 able to nearly completely and to completely
block ERK phosphorylation and measured cell survival after P-ERK1/2
blockade. Figure 4 shows that, in the presence of PD184352, EIA + raf
cells significantly died in response to serum deprivation (Figure 4A) and
to H2O2 (Figure 4B). On the contrary, EIA + Py cells were insensitive
to P-ERK1/2 blockade. However, a complete inhibition of P-ERK1/2
did not completely kill EIA + raf cells. Together, the results of Figures 2
Figure 2. PC EIA + raf cells do not show a decrease in P-ERK1/2
after serum deprivation and show a greater induction in P-ERK1/2
after H2O2 treatment with respect to PC EIA and PC EIA + Py cells.
(A, B) Dedifferentiated PC EIA and transformed PC EIA + Py and PC
EIA+ raf cellswere serum-starved (B) or exposed to 400μMH2O2 (C)
for the indicated times. Whole-cell lysates were prepared and
immunoblotted using anti–P-ERK1/2 (anti–P-Tyr 205/185) or anti-
ERK2 antibodies, as outlined in Materials and Methods. In (A) and
(B), all lines were from the same blot. Mean values (±SD) of at least
three independent experiments are shown. *P< .05, **P< .01, com-
pared with untreated cells.
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to 4 suggest that the antiapoptotic effect of v-raf is exerted, in part,
through its substrate MEK1/2, and it is related more with the relative
changes in ERK1/2 phosphorylation, after an apoptotic stimulus, than
with their absolute levels.
Importantly, we did not find any effect of v-raf on the antiapop-
totic NF-κB (whose activation by Raf is kinase-dependent but MEK-
independent). EIA + raf cells showed higher levels of IκBα than EIA +
Py cells, and after growth factor deprivation, both cell lines did not
show any NF-κB activation (Figure W2A). We also found a surpris-
ingly low level of Bcl2 in EIA + raf cells, lower than Bcl2 levels in PC
EIA and PC EIA + Py cells, which did not change after growth factor
deprivation (Figure W2B). This finding argues against a relevant anti-
apoptotic effect of v-raf mediated by Bcl2-dependent recruitment to
mitochondria [8,9,29]. Moreover, the low levels of Bcl2 in PC EIA +
raf cells were not balanced by high levels of Bcl-XL or by low levels of
Bax, and their levels did not change after growth factor deprivation
(Figure W2B).
Finally, these cell lines showed similar levels of intracellular ROS,
which directly induced cell death and parallel slight variations of ROS
levels after growth factor deprivation (slight early increase and slow late
decline; Figure W3).
Low Levels of P-ERK1/2 in EIA + raf Cells Are Caused
by a High Activity of Tyrosine Phosphatases
Next, we sought to understand the mechanism that keeps levels of
P-ERK1/2 low in EIA + raf cells. We hypothesized that phosphatase
activity may be involved. Therefore, we treated EIA + Py and EIA +
raf cells with the broad-spectrum Tyr and Ser/Thr phosphatase inhib-
itors OV and OA. As shown in Figure 5A, treatment with OV did not
have a significant effect on the levels of P-ERK1/2 in EIA + Py cells,
although it showed a dramatic effect in EIA + raf cells as detected
by anti–Tyr 205/185 (murine ERK1/ERK2) antibodies (able to detect
P-Tyr 205/185 irrespective of the state of Thr 203/183). As expected,
no variation was detected by the same antibodies after OA treatment
in both EIA + raf and EIA + Py cells (Figure W4A). To check the phos-
phorylation state of Thr 203/183, we used antibodies that detect
P-Thr 203/183 irrespective of the state of Tyr 205/185. As shown
Figure 3. EIA+ raf cells showagreater sensitivitywith respect to EIA+Py cells to theMEK inhibitor PD184352. (A) PCEIA+PyandPCEIA+
raf cells weremock-pretreated or pretreated with various concentrations of PD184352 for 30minutes and then serum-starved for 3 days in
the presence or absence of PD184352. (B) PC EIA + Py and PC EIA + raf cells were mock-pretreated or pretreated with various concen-
trations of PD184352 for 30 minutes and then exposed to 400 μMH2O2 for 30 minutes in the presence or absence of PD184352. After the
treatments described in (A) and (B), whole-cell lysates were prepared and immunoblotted using anti–P-ERK1/2 (anti–P-Tyr 205/185) or anti-
ERK2 antibodies, as outlined inMaterials andMethods. The results shown are means ± SD of at least three different experiments. *P< .05,
**P < .01.
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in Figure 5B, the P-Thr 203/183 levels were equal between EIA + Py
and EIA + raf cells and did not change after OA treatment (also as ex-
pected, after OV treatment; FigureW4B). Thus, EIA + raf cells have an
increased activity of tyrosine phosphatase(s) that decreased P-Tyr 205/
185 in normal growth conditions.
Oxidative stress inhibits phosphatase activity [30], butH2O2 andOV
increased P-ERK1/2 in EIA + raf cells by 2- to 2.2- and 5- to 6-folds,
respectively (Figure 2B vs Figure 5A). To understand this difference, we
treated EIA + Py and EIA + raf cells with H2O2 and OV separately and
together. As shown in Figure 5C , OVwas still able to increase, at the top
of the H2O2 effect, the levels of P-ERK1/2 in these cells, suggesting that
the inhibitory effect of H2O2 on phosphatase(s) was incomplete.
High Activity of Tyr Phosphatases in EIA + raf Cells Is Able
to Prevent OIS
Because oncogenic activation of the Ras-ERK pathway is able to in-
duce OIS, we reasoned that the high Tyr phosphatase activity of EIA +
raf cells might contribute to avoid senescence, concurring to the high
neoplastic phenotype of these cells.
To test this hypothesis, we first determined the effect of a Tyr phos-
phatase blockade on the growth of EIA + raf and EIA + Py cells. As
shown in Figure 6A, EIA + raf cells dramatically slowed their growth
rate (evaluated both by cell count and MTT assay) when treated with
OV. In contrast, the growth of EIA + Py cells was insensitive to OV.
Therefore, OV-increased P-ERK1/2 levels are paralleled by growth
inhibition in EIA + raf cells, whereas EIA + Py cells show absence of
OV effect both on P-ERK1/2 and on growth rate. Reciprocally, the
lack of effect of OA on P-ERK1/2 levels in both EIA + raf and EIA +
Py cells is reflected by no effect of OA on the growth of both cell lines
(Figure 6A).
Moreover, most of the EIA + raf cells (∼90%; Table 1) subjected to
the Tyr phosphatase blockade showed an intense activity of senescence-
associated β-galactosidase (SA-β-Gal; Figure 6B), a marker for senescent
or stressed cultured cells as well as for aged tissues in vivo [17]. Control
EIA + raf cells (growth in normal condition) showed a negligible SA-β-
Gal activity (5%; Table 1). By contrast, control EIA + Py cells showed
some SA-β-Gal activity (∼20%; Table 1), which was not increased on
Tyr phosphatase blockade activity (Figure 6B and Table 1). Strikingly,
the MEK-specific inhibitor PD184352 prevented the induction of
SA-β-Gal activity by OV in EIA + raf cells (Figure 6B and Table 1),
establishing a causal link between P-ERK1/2 and SA-β-Gal activity in-
duction by OV. Moreover, OV stimulated the expression of p16INK4a
in EIA + raf cells but not in EIA + Py cells (Figure 6C) and was unable
to trigger apoptosis in EIA + raf cells (Figure 6D). These observations
strongly strengthen the notion that OV is inducing cellular senescence
in EIA + raf cells (Figure 6A–D).
These results indicate that, in EIA + raf cells, a high Tyr phos-
phatase activity contributes to completely suppress OIS that instead is
present, at low levels, in control and Tyr phosphatase–inhibited EIA +
Py cells.
Interestingly, a high Tyr phosphatase activity was confirmed in
FRO anaplastic thyroid cancer cell line with the same approach used
for EIA + raf cells. Thus, OV treatment increased approximately four-
folds the P-ERK1/2 detected by anti–Tyr 205/185 (Figure 7A; and
did not increase P-ERK1/2 detected by anti–Thr 203/183; Fig-
ure W6), whereas OA treatment did not increase P-ERK1/2 detected
by both anti–Thr 203/183 (Figure 7B) and anti–Tyr 205/185
(Figure W6). Moreover, also in FRO cells, OV treatment dramatically
slowed growth rate (Figure 7C ) and caused an intense activity of SA-
β-Gal (Figure 7D).
Figure 4. The MEK inhibitor PD184352 partly sensitizes EIA + raf but not EIA + Py cells toward apoptosis. (A) PC EIA + Py cells were
mock-pretreated or pretreated with 10 and 20 μM PD184352 for 30 minutes, whereas PC EIA + raf cells were mock-pretreated or pre-
treated with 5 and 10 μM of PD184352 for 30 minutes. Cells were then serum-starved (with 0.2% BSA) for 3 days in the presence of
PD184352. (B) PC EIA + Py cells were mock-pretreated or pretreated with 10 and 20 μM of PD184352 for 30 minutes, whereas PC EIA +
raf cells were mock-pretreated or pretreated with 2.5 and 5 μM of PD184352 for 30 minutes. Cells were then exposed to 400 μM H2O2
for 48 hours in the presence of PD184352. After the treatments described in (A) and (B), cells were subjected to MTT assay, as outlined
in Materials and Methods. The results shown are mean ± SD from eight replicate wells per microtiter plate of four different experiments.
**P < .01, compared with serum-deprived or H2O2-treated cells in the absence of PD184352.
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Discussion
In this study, we propose a newmechanism bywhich, in EIA + raf trans-
formed cells, two effects, suppression of apoptosis and occurrence of
OIS, linked by a high Raf activity, are uncoupled by virtue of increased
Tyr phosphatase activity.
We used oncogene-transformed PC Cl3 cells that have been widely
used to study multistep cancerogenesis [27]. However, the mechanisms
underlying the cooperative effect of v-raf and PyMTwith EIA have not
been clearly defined, although it was clear that EIA + raf cells were more
tumorigenic than EIA + Py cells [27]. Although PC EIA cells acquire a
growth advantage with respect to PCCl3 cells, they are not transformed
[27], probably because they become highly susceptible to apoptosis
(Figure 1). Therefore, PC EIA cells behave like several oncogene-
expressing cells that become “sensitized” to various stresses [31]. The
introduction of v-raf renders PC EIA cells completely resistant to apop-
tosis by the same stimuli (Figure 1), by a mechanism, in part, MEK-
dependent (Figures 2–4). Reciprocally, EIA conceivably helps EIA + raf
cells to bypass senescence by inactivating the Rb pathway. However,
another mechanism is operational in EIA + raf cells to completely sup-
press senescence, as our data on Tyr phosphatase blockade indicate (see
below). As a result, EIA + raf cells achieved a “resistant” state and are
highly tumorigenic. We do not know exactly how PyMT transforms
PC EIA cells. Probably, part of its action relies on a partial suppression
of apoptosis, as we have seen when H2O2 is applied (Figure 1). Thus,
EIA + Py cells are reminiscent of cells in the “potentiated” state [32]
that have only partly suppressed their “sensitized” state. Our results in-
dicate that the “sensitized,” “potentiated,” and “resistant” states may be
determined by the sequential activation of only two (and not necessarily
three) oncogenes with the nature of the second determining if the
“potentiated” or the “resistant” state is achieved.
Figure 5. OV treatment increases Tyr 205/185 phosphorylation of ERK1/2 in EIA + raf but not in EIA + Py cells, whereas OA treatment
does not increase Thr 203/183 phosphorylation neither in EIA + raf nor in EIA + Py cells. (A, B) Transformed PC EIA + Py and PC EIA +
raf cells were treated with OV or OA for the indicated concentrations and times. Whole-cell lysates were prepared and immunoblotted
using anti–P-ERK1/2 (anti–P-Tyr 205/185) antibodies (able to detect P-Tyr 205/185 irrespective of the state of Thr 203/183) (A) or anti–
P-ERK1/2 (anti–Thr 203/183) antibodies (able to detect P-Thr 203/183 irrespective of the state of Tyr 205/185) (B) and anti-ERK2 anti-
bodies (A and B) as outlined in Materials and Methods. The results shown are means ± SD of at least three different experiments.
***P < .001, compared with untreated cells. Black indicates control; dark gray, 0.5 mM OV 45 minutes; light gray, 0.5 mM OV 90 min-
utes; white, 1 mM OV 45 minutes; horizontal hatched, 1 mM OV 90 minutes. (C) Transformed PC EIA + Py and PC EIA + raf cells were
treated with 0.5 mM OV or 400 μM H2O2 or 0.5 mM OV plus 400 μM H2O2 for 90 minutes. Whole-cell lysates were prepared and immuno-
blotted using anti–P-ERK1/2 (anti–Tyr 205/185) antibodies (able to detect P-Tyr 205/185 irrespective of the state of Thr 203/183) and anti-
ERK2 antibodies as outlined in Materials and Methods. The results shown are means ± SD of at least three different experiments. *P< .05,
**P < .01, ***P < .001, compared with untreated cells. Black indicates control; dark gray, 0.5 mM OV 45 minutes; light gray, 0.5 mM OV
90 minutes; white, 1 mM OV 45 minutes; horizontal hatched, 1 mM OV 90 minutes.
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Figure 6. OV treatment causes the appearance of the hallmarks of senescence in EIA + raf but not in EIA + Py cells in the absence of
apoptosis. (A) Transformed PC EIA + Py and PC EIA + raf cells were mock-treated (control) or treated with 0.5 mM OV or 60 nM OA for
90 minutes and then incubated with regular medium (without OV or OA) for 48 hours. Cells were counted and subjected to the MTT assay
before starting the 90-minute OV/OA treatments and at the end of the 48-hour period in the regular medium without OV/OA. The results
shownaremeans±SD from four plates (cell count) or eight replicatewells permicrotiter plate (MTT assay) of four independent experiments.
*P< .05, compared with untreated cells. (B) PC EIA+ raf cells weremock-pretreated (control) or treated with 2.5 μMPD184352, thenmock-
treated (control) or treated with 0.5 mMOV for 90 minutes and then incubated with regular medium (without OV) for 48 hours. PC EIA + Py
cells were mock-treated (control) or treated with 0.5 mM OV for 90 minutes and then incubated with regular medium (without OV) for
48 hours. Control, OV-treated, and PD184352-pretreated–OV-treated cells were subjected to β-galactosidase staining at the end of
the 48-hour period in the regular medium. In control and PD184352-pretreated–OV-treated EIA + raf cells, arrows indicate very few cells
weakly stained with β-galactosidase; in OV-treated EIA + raf cells, arrows indicate few cells not stained with β-galactosidase. In control
andOV-treatedEIA+Pycells, arrows indicate severalβ-galactosidase–stainedcells. (C) PCEIA+PyandPCEIA+ raf cellsweremock-treated
(controls) or treatedwith 0.5 or 1mMOV for 90minutes and then incubatedwith regularmedium (withoutOVorOA) for 48 hours.Whole-cell
lysateswere prepared and immunoblotted using anti-p16INK4a or antiactin antibodies, as outlined inMaterials andMethods. The result shown
is representative of at least three different experiments. (D) Transformed PC EIA + Py and PC EIA + raf cells were mock-treated (control)
or treatedwith 0.5 or 1mMOV for 90minutes and then incubatedwith regularmedium (withoutOVorOA) for 48 hours. Cellswere subjected
to annexin V staining at the end of the 48-hour period in the regular medium.
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The mechanisms mediating the antiapoptotic activity of Raf are
still debated. Described mechanisms require either the kinase activity
of Raf and MEK or the kinase activity of Raf but not that of MEK
(MEK-independent) or neither ones (MEK-independent/kinase-
independent mechanisms) [5–12].
We have found that v-raf has a strong antiapoptotic effect. v-raf
has a truncated N-terminus and may be unable or only partly able to
elicit a MEK-independent and kinase-independent mechanism. In fact,
v-raf should not bind MST2 because C-Raf binding to this kinase is
Table 1. Percent of SA-β-Gal–Stained Cells.
Control OV OV + PD184352
PC EIA + raf 6 ± 3 88 ± 7 9 ± 4
PC EIA + Py 18 ± 6 20 ± 8 —
The results shown are means ± SD of two replicate plates of three different experiments. For each plate,
staining was determined in four different microscope fields. The number of positively stained cells is
expressed as the percentage of the total number of cells in the analyzed field. Themicroscopic fields were
examined by two observers independently.
Figure 7. OV treatment increases Tyr 205/185 phosphorylation of ERK1/2 in FRO anaplastic thyroid cancer cells and causes the appear-
ance of the hallmarks of senescence. (A, B) FRO cells were treated with OV or OA for the indicated concentrations and times. Whole-cell
lysates were prepared and immunoblotted using anti–P-ERK1/2 (anti–P-Tyr 205/185) antibodies (able to detect P-Tyr 205/185 irrespective
of the state of Thr 203/183) (A) or anti–P-ERK1/2 (anti–Thr 203/183) antibodies (able to detect P-Thr 203/183 irrespective of the state of
Tyr 205/185) (B) and anti-ERK2 antibodies, as outlined in Materials and Methods. The results shown are means ± SD of at least three
different experiments. (C) FRO cells were mock-treated (control) or treated with 0.5 mM OV for 90 minutes and then incubated with
regular medium (without OV) for 48 hours. Cells were subjected to the MTT assay before starting the 90-minute OV treatment and at the
end of the 48-hour period in the regular medium without OV. The results shown are means ± SD from eight replicate wells per microtiter
plate of four independent experiments. (D) FRO cells were mock-treated (control) or treated with 0.5 mM OV for 90 minutes and then
incubated with regular medium (without OV) for 48 hours. Control and OV-treated cells were subjected to β-galactosidase staining at the
end of the 48-hour period in the regular medium.
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mediated by amino acids 151 to 303 of the regulatory N-terminus of
C-Raf [11]. v-raf should also be unable to elicit the survival effect
mediated by its interaction with ASK-1. Two recent observations sup-
port this hypothesis. C-Raf protects endothelial cells by genotoxic
stress by inhibiting ASK-1 at mitochondria [33] and the N-terminus
of C-Raf mediates its interaction with mitochondria as the 323 to
648 C-terminus (coincident with v-raf ) is unable to interact with
mitochondria [34].
Accordingly with these considerations, we have found that the pro-
survival effect of v-raf is, in part, MEK-dependent (Figure 4). However,
surprisingly, the P-ERK1/2 levels of EIA + raf cells, in normal serum
(Figures 2, 3, and 5), and after the application of the apoptotic stim-
ulus (Figures 2 and 3) were not greater with respect to the EIA + Py
cells. Thus, these results configure a paradox: how can lower levels of
P-ERK1/2 be protective toward apoptosis by a MEK-dependent mech-
anism, whereas higher levels cannot? We observed that apoptosis resis-
tance of EIA + raf cells correlated more with a higher dynamic range of
P-ERK1/2 after the apoptotic stimulus than with their absolute levels
(Figure 2).
The low levels of P-ERK1/2 in EIA + raf cells struck us. We reasoned
that they might reflect the presence of adaptation mechanisms like in-
creased phosphatase activity in the Ras-ERK pathway [35,36]. Indeed,
treatments with the general Tyr phosphatase inhibitor OV dramatically
increased the levels of P-ERK1/2 in EIA + raf but not in EIA + Py cells.
On the contrary, the Ser/Thr phosphatase inhibitor OA did not increase
P-ERK1/2 levels neither in EIA + raf nor in EIA + Py cells. Therefore,
EIA + raf but not EIA + Py cells have developed a high Tyr phosphatase
activity that keeps a low level of P-ERK1/2 in the face of constitutive
Raf activation.
Of note, at least some of our observations of the greater dynamic
range of P-ERK1/2 after apoptotic stimuli are explained by the higher
phosphatase activity of EIA + raf cells. Thus, P-ERK1/2 induction by
H2O2 (Figure 2B) is likely the result of Tyr phosphatase inhibition (be-
cause ROS inactivates Tyr phosphatase [30]). Therefore, EIA + raf cells,
which have a greater phosphatase activity, experience a greater P-ERK1/
2 induction after inhibition. Furthermore, the effect of serum depriva-
tion in EIA + raf cells (Figure 2A) may partly contribute to Tyr phospha-
tase inhibition by ROS, which transiently increases in this condition
(Figure W3).
Interestingly, we found that EIA + raf cells were more sensitive than
EIA + Py cells to the inhibitory action of PD184352 (Figure 3). We do
not know the reason of this differential sensitivity, but it might repre-
sent an additional factor contributing to the effectiveness of PD184352
in decreasing the survival of EIA + raf cells.
As far as the nature of the phosphatase(s) involved is concerned, it is
unlikely that a Raf phosphatase [37] or a dual-specificity phosphatase
(DUSP) [35,38] is involved. In fact, our data suggest that ERK1/2
in EIA + raf cells is selectively dephosphorylated in Tyr 205/185. If a
Raf-Tyr phosphatase or a DUSP was, in fact, involved, an increase in
both P-Tyr 205/185 and P-Thr 203/183 of ERK was expected after
inhibition. The differential phosphorylation of Tyr and Thr of the ac-
tivation loop suggests that a Tyr phosphatase acting on ERK1/2 is in-
volved. Increased expression of several Tyr phosphatases, including
some considered tumor suppressors, has been reported in a variety of
tumors [39], and ERK1/2 is increasingly demonstrated as a Tyr phos-
phatase substrate [40].
In EIA + raf cells, the phosphatase-mediated P-ERK1/2 inhibition
affects cellular senescence. The EIA gene has a senescence-inhibiting ef-
fect by inactivating the Rb pathway [41], and this mechanism should
operate in EIA + raf cells. However, in these cells, a highTyr phosphatase
activity allows a complete suppression ofOIS. Thus, onTyr phosphatase
inhibition and subsequent increase in P-ERK1/2, EIA + raf cells un-
dergo OIS in the presence of EIA. P-ERK1/2 induction was causally
linked to induction of senescence as shown by the inhibition of induc-
tion of senescence by the MEK inhibitor PD184352 (Figure 6). Analo-
gously, in EIA + Py cells, EIA inhibits senescence. However, they show
a low degree of senescence (absent in EIA + raf cells; Figures 6 and
W5), which does not increase on Tyr phosphatase inhibition, probably
linked to the absence of Tyr phosphatase activity and to the higher
P-ERK1/2 levels with respect to EIA + raf cells.
Therefore, it seems that a high phosphatase activity and, consequently,
low P-ERK1/2 levels are exploited to completely suppress senescence, a
goal not achieved when phosphatase activity is low and P-ERK1/2 levels
are higher. This is a proximal mechanism to bypass senescence, directly
opposing, at the posttranslational level, the abrupt oncogene-induced
ERK stimulation. It is at variance with distal mechanisms opposing
the Rb and p53 pathways such as inactivation of the INK4α/ARF
locus [23].
Strikingly, in EIA + raf cells, the phosphatase-mediated P-ERK1/2
inhibition, instrumental to bypass senescence, paradoxically coexists
with a MEK-dependent protection from apoptosis, as pointed out be-
fore. We propose that the survival effect of raf is not a function of
absolute P-ERK1/2 levels at a given time but, rather, is dynamically
dependent on greater variations after an apoptotic stimulus. It may
seem contradictory that positive variations of P-ERK1/2 both protect
toward apoptosis and trigger senescence. This may rely on the different
dynamic ranges of P-ERK1/2 induction: absence of diminution (serum
deprivation) or 2- to 2.5-folds induction (H2O2 treatment) protect
toward apoptosis, whereas 5- to 6-folds induction triggers senescence
(directly compared in Figure 5C ).
The lack of correlation described here between the expression of
constitutively activated Raf and P-ERK is reminiscent of what has been
found in some human tumors. Thus, ERK1/2 activation does not
correlate with K-Ras and B-Raf status in endometrial cancers [42], with
N-Ras and B-Raf status inmelanomas [43], and with the B-Raf status in
papillary thyroid carcinoma [44]. In some cases, even a paradoxical cor-
relation between low P-ERK1/2 levels and adverse prognosis has been
found [42,45,46]. The results presented heremay help to interpret these
poorly understood in vivo observations and to identify new therapeutic
targets in the actively investigated Tyr phosphatase family.
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Figure W1. EIA + raf cells express a high level of p79 gag-raf poly-
protein. PC EIA + Py and PC EIA + raf cells, grown in normal condi-
tions (5% calf serum), were harvested, and whole-cell lysates were
immunoblotted with anti–C-Raf antibodies (A). For control of load-
ing, the filter was stained with Ponceau S (B).
Figure W2. NF-κB is not activated in EIA+ raf andEIA+Pycells after
growth factor deprivation. EIA + raf cells show lower levels of Bcl2
and equal levels of Bcl-XL and Bax with respect to EIA + Py cells.
Cells were kept in the presence of serum or deprived of serum in
the presence of 0.2% BSA for 48 hours. At the end of this period in
the serum-starvedmedium, cells were harvested.Whole-cell lysates
were prepared and immunoblotted using anti-IκBα, anti-Bcl2, anti–
Bcl-XL, and anti-Bax antibodies asoutlined inMaterials andMethods.
Figure W3. Estimation of intracellular ROS level. Cells were kept in the presence of serumor deprived of serum in the presence of 0.2%BSA
for various periods. Floating and adherent cells were collected by mild trypsinization, washed in PBS, and resuspended in PBS, 10 μM
5,6-carboxy-2′,7′-dichlorofluorescein diacetate (DCFH-DA; Molecular Probes, Inc, Eugene, OR), 5 μg/ml propidium iodide at 37°C, and kept
in DCFH-DA thereafter. DCFH-DA is a compound taken up by the cells and trapped in a nonfluorescent deacylated form (DCFH). DCFH is
oxidized by ROS to a fluorescent form. After 1 hour of incubation, cells were analyzed by FACScanwith excitation at 495-nm and emission at
525-nmwavelengths. Nonintact cells leak DCFH but were stained by propidium iodide and excluded. The results shown are means ± SD of
at least three different experiments.
Figure W4. OA treatment does not increase Tyr 205/185 phosphorylation, and OV treatment does not increase Thr 203/183 phosphoryla-
tion neither in EIA + raf nor in EIA+Py cells. EIA + raf and EIA+Py cells were treated with OA (A) or OV (B) for the indicated concentrations
and times. Whole cell lysates were prepared and immunoblotted using anti–P-ERK1/2 (anti–P-Tyr 205/185 antibodies, able to detect P-Tyr
205/185 irrespective of the state of Thr 203/183) (A) and anti–P-ERK1/2 (anti–Thr 203/183 antibodies, able to detect P-Thr 203/183 irrespec-
tive of the state of Tyr 205/185) (B), and anti-ERK2 antibodies, as outlined in Materials and Methods. In (A), the results shown are means ±
SD of three independent experiments. In (B), a representative experiment of three independent experiments is shown.
Figure W5. OA treatment does not cause the appearance of the hallmarks of senescence in both EIA + raf and EIA + Py cells. Transformed
PC EIA + raf and PC EIA+Py cells were mock-treated or treated with 60 nM OA for 90 minutes and then incubated with regular medium
(without OA) for 48 hours. Control and OA-treated cells were subjected to β-galactosidase staining at the end of the 48-hour period in the
regular medium without OA.
Figure W6. OA treatmentdoesnot increase Tyr 205/185phosphoryl-
ation, and OV treatment does not increase Thr 203/183 phosphoryla-
tion in FRO anaplastic thyroid cancer cells. FRO cells were treated
with OA or OV for the indicated concentrations and times. Whole-
cell lysates were prepared and immunoblotted using anti–P-ERK1/2
(anti–P-Tyr 205/185 antibodies, able to detect P-Tyr 205/185 irrespec-
tive of the state of Thr 203/183) and anti–P-ERK1/2 (anti–Thr 203/183
antibodies, able to detect P-Thr 203/183 irrespective of the state of
Tyr 205/185) and anti-ERK2 antibodies, as outlined in Materials and
Methods. A representative experiment of three independent experi-
ments is shown.
